Evacetrapib
Phase 3Small molecule
Eli LillyEvacetrapib was being developed to help lower cholesterol and reduce the risk of heart disease by increasing the amount of 'good cholesterol' (HDL) in the blood.[1] Evacetrapib is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Evacetrapib is one of 148 small molecule programs targeting Hepatic failure. It is currently in Phase 3.
5
Indications
21
Total Trials
0
Active Trials
147
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Evacetrapib
Eli LillyPhase 3
Injectafer
AAmerican Regent, Inc.
Phase 3
Spiriva
Boehringer IngelheimPhase 3
Repatha
AmgenPreclinical
Mounjaro
Eli LillyPreclinical
Praluent
RegeneronPreclinical
Myrbetriq
AstellasPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Farxiga
AstraZenecaPreclinical
Benicar
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
ART12 trials
Show 9 more trials
Hypercholesterolemia2 trials
Cholesterol2 trials
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Evacetrapib. EMBL-EBI & Wellcome Sanger Institute.
- [4]